A US Food and Drug Administration draft guidance on clinical considerations for individualized antisense oligonucleotide drug products emphasizes the limited target population for such treatments.
The guidance describes clinical considerations for investigational new drug application (IND) submissions to support initial and continued administration, dosing and clinical monitoring of an individual with a severely debilitating and life-threatening genetic disease who is
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?